

Alexandre Karras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3868346/publications.pdf>

Version: 2024-02-01

151
papers

8,021
citations

50276

46
h-index

53230

85
g-index

158
all docs

158
docs citations

158
times ranked

8016
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. New England Journal of Medicine, 2014, 371, 1771-1780.	27.0	842
2	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney International, 2012, 82, 454-464.	5.2	454
3	Tenofovir-Related Nephrotoxicity in Human Immunodeficiency Virus-Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus. Clinical Infectious Diseases, 2003, 36, 1070-1073.	5.8	339
4	Rituximab plus Peg-interferon- α /ribavirin compared with Peg-interferon- α /ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood, 2010, 116, 326-334.	1.4	248
5	INF2 Mutations in Charcot-Marie-Tooth Disease with Glomerulopathy. New England Journal of Medicine, 2011, 365, 2377-2388.	27.0	235
6	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Annals of the Rheumatic Diseases, 2018, 77, 1143-1149.	0.9	219
7	Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation, 2004, 77, 238-243.	1.0	166
8	Large Artery Stiffening and Remodeling Are Independently Associated With All-Cause Mortality and Cardiovascular Events in Chronic Kidney Disease. Hypertension, 2012, 60, 1451-1457.	2.7	161
9	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2017, 76, 1662-1668.	0.9	159
10	Rituximab in Severe Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 579-587.	4.5	151
11	The Spectrum of Type I Cryoglobulinemia Vasculitis. Medicine (United States), 2013, 92, 61-68.	1.0	150
12	Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 50-59.	4.5	148
13	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. Journal of Antimicrobial Chemotherapy, 2010, 65, 2628-2640.	3.0	141
14	Mutations in INF2 Are a Major Cause of Autosomal Dominant Focal Segmental Glomerulosclerosis. Journal of the American Society of Nephrology: JASN, 2011, 22, 239-245.	6.1	138
15	Arterial Remodeling Associates with CKD Progression. Journal of the American Society of Nephrology: JASN, 2011, 22, 967-974.	6.1	135
16	Acute Renal Infarction. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 392-398.	4.5	135
17	Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood, 2017, 129, 1437-1447.	1.4	120
18	Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy. JAMA - Journal of the American Medical Association, 2017, 318, 2099.	7.4	120

#	ARTICLE	IF	CITATIONS
19	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Annals of Internal Medicine</i> , 2020, 173, 179-187.	3.9	116
20	A Clinicopathologic Study of Thrombotic Microangiopathy in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 137-148.	6.1	115
21	Patterns of Noncryoglobulinemic Glomerulonephritis with Monoclonal Ig Deposits. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1609-1616.	4.5	114
22	Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. <i>Kidney International</i> , 2011, 79, 643-654.	5.2	108
23	Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup study of thirty-two patients. <i>Arthritis and Rheumatism</i> , 2009, 60, 2531-2540.	6.7	99
24	Association of Kidney Function, Vitamin D Deficiency, and Circulating Markers of Mineral and Bone Disorders in CKD. <i>American Journal of Kidney Diseases</i> , 2011, 58, 544-553.	1.9	97
25	Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. <i>Journal of Clinical Virology</i> , 2006, 35, 257-263.	3.1	95
26	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. <i>Kidney International</i> , 2017, 92, 1232-1241.	5.2	93
27	Renal and thymic pathology in thymoma-associated nephropathy: report of 21 cases and review of the literature. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1075-1082.	0.7	89
28	PegIFN- α /ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. <i>Journal of Hepatology</i> , 2015, 62, 24-30.	3.7	86
29	Rituximab in anti-GBM disease: A retrospective study of 8 patients. <i>Journal of Autoimmunity</i> , 2015, 60, 74-79.	6.5	84
30	High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. <i>Kidney International</i> , 2015, 88, 386-395.	5.2	84
31	Long-term Kidney Disease Outcomes in Fibrillary Glomerulonephritis: A Case Series of 27 Patients. <i>American Journal of Kidney Diseases</i> , 2013, 62, 679-690.	1.9	75
32	Insights From the Use in Clinical Practice of Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 Cases. <i>American Journal of Kidney Diseases</i> , 2014, 63, 40-48.	1.9	74
33	Atypical and secondary hemolytic uremic syndromes have a distinct presentation and common genetic risk factors. <i>Kidney International</i> , 2019, 95, 1443-1452.	5.2	74
34	Observations of a large Dent disease cohort. <i>Kidney International</i> , 2016, 90, 430-439.	5.2	71
35	Oxalate Nephropathy Associated with Chronic Pancreatitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1895-1902.	4.5	70
36	Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. <i>Kidney International</i> , 2011, 79, 635-642.	5.2	67

#	ARTICLE	IF	CITATIONS
37	Mutation Update of the <i>CLCN5</i> Gene Responsible for Dent Disease 1. Human Mutation, 2015, 36, 743-752.	2.5	66
38	Renal involvement in monoclonal (type I) cryoglobulinemia: Two cases associated with IgG3 κ cryoglobulin. American Journal of Kidney Diseases, 2002, 40, 1091-1096.	1.9	65
39	Rapamycin-induced oligospermia. Transplantation, 2003, 76, 885-886.	1.0	63
40	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Medicale, 2013, 42, 1317-1330.	1.9	62
41	Timing and Determinants of Erythropoietin Deficiency in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 35-42.	4.5	60
42	Performance of GFR Estimating Equations in African Europeans: Basis for a Lower Race-Ethnicity Factor Than in African Americans. American Journal of Kidney Diseases, 2013, 62, 182-184.	1.9	60
43	Aortic Stiffness of Kidney Transplant Recipients Correlates with Donor Age. Journal of the American Society of Nephrology: JASN, 2008, 19, 798-805.	6.1	58
44	ANCA-associated vasculitis in patients with primary Sjögren's syndrome: Detailed analysis of 7 new cases and systematic literature review. Autoimmunity Reviews, 2015, 14, 742-750.	5.8	52
45	Successful Renal Retransplantation after Post-Transplant Lymphoproliferative Disease. American Journal of Transplantation, 2004, 4, 1904-1909.	4.7	51
46	Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis. Nature Communications, 2017, 8, 1829.	12.8	50
47	Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leukemia and Lymphoma, 2013, 54, 767-777.	1.3	49
48	A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 1924-1932.	6.1	46
49	What nephrologists need to know about hemophagocytic syndrome. Nature Reviews Nephrology, 2009, 5, 329-336.	9.6	44
50	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 1213-1224.	6.1	44
51	Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrology Dialysis Transplantation, 2012, 27, 1924-1930.	0.7	43
52	Presentation and Prognosis of Cardiac Involvement in Hepatitis C Virus-Related Vasculitis. American Journal of Cardiology, 2013, 111, 265-272.	1.6	43
53	Porphyria and kidney diseases. CKJ: Clinical Kidney Journal, 2018, 11, 191-197.	2.9	43
54	Excessive interleukin-15 transpresentation endows NKG2D+CD4+ T cells with innate-like capacity to lyse vascular endothelium in granulomatosis with polyangiitis (Wegener's). Arthritis and Rheumatism, 2011, 63, 2116-2126.	6.7	42

#	ARTICLE	IF	CITATIONS
55	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. <i>Frontiers in Immunology</i> , 2018, 9, 2260.	4.8	42
56	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 881-893.	0.8	39
57	A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. <i>Rheumatology</i> , 2017, 56, kew376.	1.9	38
58	Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated Receptor β Essential for Resistance to Crescentic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 172-188.	6.1	38
59	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. <i>Nephrology Dialysis Transplantation</i> , 2017, 33, 1579-1590.	0.7	37
60	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020, 19, 102671.	5.8	37
61	COVID-19-Related Collapsing Glomerulopathy in a Kidney Transplant Recipient. <i>American Journal of Kidney Diseases</i> , 2020, 76, 590-594.	1.9	37
62	Nephronophthisis related to homozygous NPHP1 gene deletion as a cause of chronic renal failure in adults. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2660-2663.	0.7	36
63	Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. <i>CKJ: Clinical Kidney Journal</i> , 2016, 10, sfw101.	2.9	36
64	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. <i>Journal of Autoimmunity</i> , 2015, 65, 49-55.	6.5	34
65	Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1661-1668.	0.7	32
66	Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease. <i>Kidney International</i> , 2019, 96, 1020-1029.	5.2	32
67	Proteomic analysis of neutrophils in ANCA-associated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1 involved in apoptotic cell clearance. <i>Kidney International</i> , 2019, 96, 397-408.	5.2	32
68	Urinary Retinol Binding Protein Is a Marker of the Extent of Interstitial Kidney Fibrosis. <i>PLoS ONE</i> , 2014, 9, e84708.	2.5	32
69	Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1894-1902.	0.7	29
70	Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 514-521.	4.5	29
71	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. <i>Rheumatology</i> , 2021, 60, 359-365.	1.9	27
72	Ifosfamide nephrotoxicity in adult patients. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 660-665.	2.9	26

#	ARTICLE	IF	CITATIONS
73	Microscopic Polyangiitis: New Insights into Pathogenesis, Clinical Features and Therapy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 459-464.	2.1	25
74	Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. <i>Journal of Autoimmunity</i> , 2020, 112, 102467.	6.5	25
75	Reversal of Arterial Stiffness and Maladaptive Arterial Remodeling After Kidney Transplantation. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	24
76	Fasting Urinary Osmolality, CKD Progression, and Mortality: A Prospective Observational Study. <i>American Journal of Kidney Diseases</i> , 2019, 73, 596-604.	1.9	24
77	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2647-2657.	1.6	24
78	Reappraisal of Renal Arteritis in ANCA-associated Vasculitis: Clinical Characteristics, Pathology, and Outcome. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2362-2374.	6.1	24
79	Renal Function Decline Under Therapy With Small Interfering RNA Silencing ALAS1 for Acute Intermittent Porphyria. <i>Kidney International Reports</i> , 2021, 6, 1904-1911.	0.8	24
80	Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. <i>BMC Nephrology</i> , 2021, 22, 267.	1.8	24
81	COMPLICATIONS OF PROTOCOL RENAL BIOPSY. <i>Transplantation</i> , 2004, 77, 1475-1476.	1.0	23
82	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 339-346.	3.4	22
83	Rituximab Treatment for Membranous Nephropathy: A French Clinical and Serological Retrospective Study of 28 Patients. <i>Nephron Extra</i> , 2011, 1, 251-261.	1.1	20
84	An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). <i>Kidney International</i> , 2018, 94, 1217-1226.	5.2	20
85	Confirmation of the low clinical effect of human herpesvirus 6 and 7 infections after renal transplantation. <i>Journal of Medical Virology</i> , 2012, 84, 450-456.	5.0	19
86	Rule-Mining for the Early Prediction of Chronic Kidney Disease Based on Metabolomics and Multi-Source Data. <i>PLoS ONE</i> , 2016, 11, e0166905.	2.5	19
87	Tissue-Specific Microvascular Endothelial Cells Show Distinct Capacity To Activate NK Cells: Implications for the Pathophysiology of Granulomatosis with Polyangiitis. <i>Journal of Immunology</i> , 2014, 192, 3399-3408.	0.8	18
88	Specific changes in faecal microbiota are associated with familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1398-1404.	0.9	18
89	Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 609-617.	0.7	18
90	Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>JAMA Network Open</i> , 2022, 5, e2220925.	5.9	18

#	ARTICLE	IF	CITATIONS
91	Extracellular Fluid Volume Is an Independent Determinant of Uncontrolled and Resistant Hypertension in Chronic Kidney Disease: A NephroTest Cohort Study. <i>Journal of the American Heart Association</i> , 2018, 7, e010278.	3.7	17
92	Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 519-530.	3.1	16
93	Urinary Angiogenin Reflects the Magnitude of Kidney Injury at the Infrahistologic Level. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 678-690.	6.1	15
94	Survival and specific outcome of sickle cell disease patients after renal transplantation. <i>British Journal of Haematology</i> , 2019, 187, 676-680.	2.5	15
95	Cardiovascular risk associated with high sodium-containing drugs: A systematic review. <i>PLoS ONE</i> , 2017, 12, e0180634.	2.5	13
96	Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 964-972.	4.5	13
97	APOL1 risk genotype in European steroid-resistant nephrotic syndrome and/or focal segmental glomerulosclerosis patients of different African ancestries. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1885-1893.	0.7	12
98	Nephronophthisis in Young Adults Phenocopying Thrombotic Microangiopathy and Severe Nephrosclerosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 615-617.	4.5	12
99	Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity. <i>PLoS ONE</i> , 2021, 16, e0252026.	2.5	12
100	Spondyloarthritis-Associated IgA Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 813-820.	0.8	12
101	Successful Treatment of Acute Thrombotic Microangiopathy by Eculizumab After Combined Lung and Kidney Transplantation. <i>Transplantation</i> , 2013, 96, e58-e59.	1.0	11
102	ANCA-Negative Pauci-immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification. <i>American Journal of Kidney Diseases</i> , 2022, 79, 56-68.e1.	1.9	11
103	Effectiveness of a "do not interrupt"™ vest intervention to reduce medication errors during medication administration: a multicenter cluster randomized controlled trial. <i>BMC Nursing</i> , 2021, 20, 153.	2.5	11
104	ANCA-associated diseases and lung carcinomas: a five-case series. <i>Clinical Nephrology</i> , 2014, 81, 132-137.	0.7	11
105	New insights on IgA vasculitis with underlying solid tumor: a nationwide French study of 30 patients. <i>Clinical Rheumatology</i> , 2021, 40, 1933-1940.	2.2	10
106	Molecular Signatures of Kidney Antibody-Secreting Cells in Lupus Patients With Active Nephritis Upon Immunosuppressive Therapy. <i>Arthritis and Rheumatology</i> , 2021, 73, 1461-1466.	5.6	10
107	Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant. <i>Clinical Transplantation</i> , 2007, 21, 295-300.	1.6	9
108	Podocytes and Proteinuria in ANCA-Associated Glomerulonephritis: A Case-Control Study. <i>Frontiers in Immunology</i> , 2019, 10, 1405.	4.8	9

#	ARTICLE	IF	CITATIONS
109	A urinary cause of coma. Journal of Neurology, 2011, 258, 941-943.	3.6	8
110	From arterial stiffness to kidney graft microvasculature: Mortality and graft survival within a cohort of 220 kidney transplant recipients. PLoS ONE, 2018, 13, e0195928.	2.5	8
111	Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry. Arthritis and Rheumatology, 2021, 73, 641-650.	5.6	8
112	Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. Kidney International Reports, 2021, 6, 746-754.	0.8	8
113	Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. Rheumatology, 2022, 61, 2464-2471.	1.9	8
114	Nephrotoxicity Associated With Niraparib. American Journal of Kidney Diseases, 2020, 76, 898-900.	1.9	8
115	Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1665-1675.	4.5	8
116	Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study. Journal of Internal Medicine, 2021, , .	6.0	8
117	Cryoglobulin-Induced Cardiomyopathy. Journal of the American College of Cardiology, 2010, 55, e13.	2.8	7
118	Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury. Pharmacoepidemiology and Drug Safety, 2019, 28, 1583-1590.	1.9	7
119	Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. Molecular Genetics and Metabolism, 2020, 131, 259-266.	1.1	7
120	Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology, 2020, 59, 2970-2975.	1.9	7
121	The impact of interventions by pharmacists collected in a computerised physician order entry context: a prospective observational study with a 10-year reassessment. Swiss Medical Weekly, 2019, 149, w20015.	1.6	7
122	Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series. American Journal of Kidney Diseases, 2022, 80, 341-352.	1.9	7
123	Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis. Journal of Autoimmunity, 2016, 72, 57-64.	6.5	6
124	Extreme hypomagnesemia: characteristics of 119 consecutive inpatients. Internal and Emergency Medicine, 2018, 13, 1201-1209.	2.0	6
125	Less arterial stiffness in kidney transplant recipients than chronic kidney disease patients matched for renal function. CKJ: Clinical Kidney Journal, 2021, 14, 1244-1254.	2.9	6
126	The urinary metabolome of chronic kidney disease. Kidney International, 2014, 85, 1239-1240.	5.2	5

#	ARTICLE	IF	CITATIONS
127	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 701273.	4.8	5
128	Baroreflex sensitivity after kidney transplantation: arterial or neural improvement?. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2401-2403.	0.7	4
129	Hyponatremia and Mortality in Patients With Cancer: The Devil Is in the Details. <i>American Journal of Kidney Diseases</i> , 2012, 59, 168-169.	1.9	3
130	Cholesterol Crystal Embolization after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2019, 381, 655-655.	27.0	3
131	Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 298.	2.4	3
132	Lymphomas with kidney involvement: the French multicenter retrospective LyKID study. <i>Leukemia and Lymphoma</i> , 2020, 61, 887-895.	1.3	3
133	Natural Killer Cell Large Granular Lymphocyte Leukemia-Induced Glomerulonephritis. <i>Kidney International Reports</i> , 2021, 6, 1174-1177.	0.8	3
134	L39. Fulminant anca vasculitis. <i>Presse Medicale</i> , 2013, 42, 607-609.	1.9	2
135	Acute interstitial nephritis: aetiology and management. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1799-1802.	0.7	2
136	Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer. <i>European Journal of Cancer</i> , 2021, 147, 60-62.	2.8	2
137	French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis. <i>Presse Medicale</i> , 2022, 51, 104107.	1.9	2
138	Rein et lupus : données récentes. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2005, 72, 162-167.	0.0	1
139	Type III Cryoglobulinemia Complicated by Renal Cortical Necrosis. <i>American Journal of Kidney Diseases</i> , 2005, 45, e79-e81.	1.9	1
140	Systemic Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1912-1915.	4.5	1
141	Atteintes rénales dans les spondyloarthrites. <i>Revue Du Rhumatisme Monographies</i> , 2015, 82, 22-26.	0.0	1
142	355. FACTORS PREDICTING SEVERE INFECTIONS IN PATIENTS WITH SYSTEMIC NECROTIZING VASCULITIDES BASED ON DATA FROM 733 PATIENTS ENROLLED IN RANDOMIZED-CONTROLLED TRIALS. <i>Rheumatology</i> , 2019, 58, .	1.9	1
143	B-cell treatment in ANCA-associated vasculitis. <i>Rheumatology</i> , 2020, 59, iii68-iii73.	1.9	1
144	Epstein-Barr virus-associated smooth muscle tumor in a kidney transplant recipient: A case-report and review of the literature. <i>Transplant Infectious Disease</i> , 2021, 23, e13456.	1.7	1

#	ARTICLE	IF	CITATIONS
145	Quiz Page April 2016. American Journal of Kidney Diseases, 2016, 67, A17-A19.	1.9	0
146	The Case A man with hypertension, respiratory distress, and rapidly progressive renal failure. Kidney International, 2016, 89, 509-510.	5.2	0
147	255.â€fRENAL INVOLVEMENT IN EGPA: A MULTICENTRE RETROSPECTIVE STUDY OF 63 CASES. Rheumatology, 2019, 58, .	1.9	0
148	Local miscommunications between glomerular cells as potential therapeutic targets for crescentic glomerulonephritides. Nephrologie Et Therapeutique, 2019, 15, S1-S5.	0.5	0
149	THU0211â€...EVOLUTION OF KIDNEY ANTIBODY SECRETING CELLS MOLECULAR SIGNATURE IN LUPUS PATIENTS WITH ACTIVE NEPHRITIS UPON IMMUNOSUPPRESSIVE THERAPY. , 2019, , .		0
150	O19â€...Evolution of kidney antibody secreting cells molecular signature in lupus patients with active nephritis upon immunosuppressive therapy. , 2020, , .		0
151	Glomerulonephritis with non-Randall-type, non-cryoglobulinemic monoclonal immunoglobulin G deposits [PGNMID and ITC]. CKJ: Clinical Kidney Journal, 0, , .	2.9	0